(VIANEWS) – Shares of Zai Lab (NASDAQ: ZLAB) slid by a staggering 22.11% in 10 sessions from $40.38 to $31.45 at 14:23 EST on Wednesday, after five consecutive sessions in a row of losses. NASDAQ is dropping 0.76% to $11,341.18, after two successive sessions in a row of gains.
Zai Lab’s last close was $31.50, 41.61% under its 52-week high of $53.95.
About Zai Lab
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Earnings Per Share
As for profitability, Zai Lab has a trailing twelve months EPS of $-3.46.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -44.05%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Zai Lab’s stock is considered to be overbought (>=80).
Sales Growth
Zai Lab’s sales growth is 27.6% for the ongoing quarter and 40.9% for the next.
Moving Average
Zai Lab’s worth is way below its 50-day moving average of $39.62 and way under its 200-day moving average of $36.95.
Revenue Growth
Year-on-year quarterly revenue growth grew by 33.5%, now sitting on 196.61M for the twelve trailing months.
More news about Zai Lab (ZLAB).
